Andere Sprachen Acurx Pharmaceuticals, Inc.

Aktien

A3CSCG

US00510M1045

ACXP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.05.2024			% 5 Tage	% 1. Jan.
1,97 ^USD	-5,29 %		-10,45 %	-48,56 %

02.05.	Acurx Pharmaceuticals, Inc. gibt die Präsentation der Ergebnisse der klinischen Phase-2-Studie mit Ibezapolstat auf der ESCMID Global Scientific Conference bekannt	CI
04.04.	Top Premarket Gainers	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference	02.05.
Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference	02.05.
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference	25.04.
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update	23.04.
Top Premarket Gainers	04.04.
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV	21.03.
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19.03.
US Futures Trend Lower in Tuesday's Premarket as Investors Await Start of 2-Day Fed Meeting	19.03.
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	18.03.
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.03.
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update	04.03.
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV	01.03.
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development	27.02.
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients	29.01.
Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients	29.01.
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024, February 1, 2024	24.01.
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024	23.01.
Acurx Pharmaceuticals' Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)	22.01.
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients	17.01.
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients	17.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Acurx Pharmaceuticals, Inc.

Aktien

A3CSCG

US00510M1045

ACXP

Andere Sprachen

Filter